|
Can’t access the links? Add “lnks.gd” to the allowlist of your content blocking software. |
|
|
The Health Care Authority (HCA) is now accepting applications from small providers to participate in the long-acting injectable (LAI) buprenorphine funding program.
This program supports small providers who serve uninsured patients with opioid use disorder (OUD) by covering the cost of LAI buprenorphine.
Application period
-
Open: January 13, 2026.
-
Close: End of day February 13, 2026.
About the LAI buprenorphine funding program
The LAI buprenorphine funding program is a ship to/bill to model that allows small providers to stock LAI buprenorphine in their clinic at no cost. Uninsured patients with OUD can start treatment right away, instead of delaying care while waiting for the medication to arrive.
Small providers are defined as a clinic with five or fewer licensed prescribers that prescribe Sublocade or Brixadi. These clinics may not be owned or operated by a hospital or carceral facility.
This program ends on June 30, 2027 or when funding is exhausted.
Find out more about this program, eligibility, and the application process in the frequently asked questions (FAQ).
|
|
|
|